The cost of Mounjaro, a prominent weight-loss injection, is set to increase significantly in the UK, causing widespread concern among patients and sparking a temporary halt in shipments from manufacturer Eli Lilly. Initially announced to more than double in price, commercial deals have since adjusted the highest dose's wholesale price to £247.50 a month from £122, an increase of over 100 percent. Lower doses will also see price hikes, with the 5mg dose rising from £92 to £135.

This price surge, coupled with a 'postcode lottery' for NHS prescriptions, has created significant challenges for those relying on the drug. Many patients who initially self-funded their treatment now find themselves ineligible for NHS prescriptions because they have lost too much weight to meet the strict criteria. Julia Dore, 51, who shed five-and-a-half stone privately on Mounjaro, faced the distressing prospect of having to regain weight to qualify for an NHS prescription. Similarly, Jenny Lloyd, 50, who saw her diabetes go into remission and improved mobility after private treatment, was told her BMI was now too low for an NHS prescription.

An analysis revealed that less than half of England's Integrated Care Boards (ICBs) have begun prescribing Mounjaro, with funding for eligible patients varying drastically. Some areas could cover over 70 percent of eligible patients, while others like Coventry and Warwickshire had funding for as little as 21 percent. This disparity has been criticized as a